An international team of scientists, researchers and interoperability experts will evaluate biosensors that can track an individual's physiology, behavior, and environment to improve seizure prediction.
LivaNova says a new cost analysis found that Vagus Nerve Stimulation Therapy (VNS Therapy) System results in lower resource utilization and lower cost for drug-resistant epilepsy patients when compared to continued treatment with anti-epileptic drugs.
Pediatric Epilepsy
The report shows that there continues to be a steady flow of potential antiepileptic drugs progressing to clinical development.
Pediatric Epilepsy
Rapamycin therapy exhibits positive effects on epileptic seizures in cases of TSC in 1-2 ?years but these positive effects on seizure control of rapamycin therapy decline after the second year.
Researchers identify 10 knowledge gaps and propose experiments to close these. If adequately addressed, biofluid microRNAs may be an important future source of diagnostic biomarkers that could also support forthcoming trials of anti?epileptogenesis or disease?modifying therapies.
Discover the latest about what's happening at CURE and in our community in the October 2018 CURE Update from Chief Scientific Officer, Laura Lubbers!
Pediatric Epilepsy
This study suggests that the risk of infantile spasms relapse in TSC may be reduced by high-dose vigabatrin treatment.
Learn why CBD may be an effective treatment for certain types of epilepsy, what risks can be associated with CBD, and what the FDA approval of means for the future of epilepsy research and treatment.
Fycompa received approval from the FDA for an indication expansion to cover partial-onset seizures in pediatric patients with epilepsy 4 years of age and older.
